Omeros Corporation (NASDAQ:OMER), a biopharmaceutical company committed to discovering, developing and commercializing both small-molecule and protein therapeutics for large-market as well as orphan indications …
Omeros Corporation (NASDAQ:OMER) announced initiation of patient dosing in its OMS721 Phase 2 program in corticosteroid-dependent renal diseases. The Phase 2 clinical trial of …
Omeros Corporation (NASDAQ:OMER), a biopharmaceutical company committed to discovering, developing and commercializing both small-molecule and protein therapeutics for large-market as well as orphan …
Omeros Corporation (NASDAQ:OMER) announced that it has launched OMIDRIAssure™, a comprehensive reimbursement services program to provide expanded access to Omidria® (phenylephrine and ketorolac injection) …
Needham & Company analyst Serge Belanger weighed in on biotechnology companies Omeros Corporation (NASDAQ:OMER) and Senomyx Inc. (NASDAQ:SNMX) on August 31, rating both …
I’ve been saying this all year. Ultimately, Gilead Sciences, Inc.
In a research report released today, Wedbush analyst Liana Moussatos reiterated an Outperform rating on shares of Omeros Corporation (NASDAQ:OMER) and raised the price …
